Angiogenic markers in canine lymphoma tissues do not predict survival times in chemotherapy treated dogs
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F12%3A10118885" target="_blank" >RIV/00216208:11140/12:10118885 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/49777513:23520/12:43914887
Výsledek na webu
<a href="http://www.sciencedirect.com/science/article/pii/S0034528811001706" target="_blank" >http://www.sciencedirect.com/science/article/pii/S0034528811001706</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.rvsc.2011.04.018" target="_blank" >10.1016/j.rvsc.2011.04.018</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Angiogenic markers in canine lymphoma tissues do not predict survival times in chemotherapy treated dogs
Popis výsledku v původním jazyce
Angiogenesis, which is essential for malignancies to progress, depends on various signalling proteins including vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptors 1 and 2 (VEGFR-1 and VEGFR-2). Microvessel density(MVD) is frequently used to evaluate angiogenesis. This study assessed the relationship between expression of VEGF, VEGFR-1 and VEGFR-2, MVD and the survival time in dogs with lymphoma. VEGF, VEGFR-1 and VEGFR-2 expression was evaluated immunohistochemically and microvessel profiles were counted in 34 lymphoma samples. Seventy-nine percent of the samples showed high VEGF expression and 62% were highly positive for VEGFR-1; VEGFR-2 immunoreactivity was mostly negative. Dogs treated with chemotherapy hada median survival time of 266days, but no significant relationships were found between overall survival time, MVD and expression of VEGF, VEGFR-1 or VEGFR-2. In this study, VEGF its receptors and the MVD were no prognostic factors in dogs
Název v anglickém jazyce
Angiogenic markers in canine lymphoma tissues do not predict survival times in chemotherapy treated dogs
Popis výsledku anglicky
Angiogenesis, which is essential for malignancies to progress, depends on various signalling proteins including vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptors 1 and 2 (VEGFR-1 and VEGFR-2). Microvessel density(MVD) is frequently used to evaluate angiogenesis. This study assessed the relationship between expression of VEGF, VEGFR-1 and VEGFR-2, MVD and the survival time in dogs with lymphoma. VEGF, VEGFR-1 and VEGFR-2 expression was evaluated immunohistochemically and microvessel profiles were counted in 34 lymphoma samples. Seventy-nine percent of the samples showed high VEGF expression and 62% were highly positive for VEGFR-1; VEGFR-2 immunoreactivity was mostly negative. Dogs treated with chemotherapy hada median survival time of 266days, but no significant relationships were found between overall survival time, MVD and expression of VEGF, VEGFR-1 or VEGFR-2. In this study, VEGF its receptors and the MVD were no prognostic factors in dogs
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
EA - Morfologické obory a cytologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
<a href="/cs/project/ME09090" target="_blank" >ME09090: Design kvantitativních studií v histologii - strategie vzorkování a detekce struktur, testování spolehlivosti a reprodukovatelnosti kvantitativních analýz</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)
Ostatní
Rok uplatnění
2012
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Research in Veterinary Science
ISSN
0034-5288
e-ISSN
—
Svazek periodika
92
Číslo periodika v rámci svazku
3
Stát vydavatele periodika
GB - Spojené království Velké Británie a Severního Irska
Počet stran výsledku
7
Strana od-do
444-450
Kód UT WoS článku
000302985000017
EID výsledku v databázi Scopus
—